Premier Biomedical Inc (OTCMKTS:BIEI) and Advanced Technologies Solutions (ATS) have signed a partnership deal that will allow them to work together towards the treatment of neuropathic and localized pain.
The two firms signed a letter of intent formalizing their joint venture whose intention is to develop and distribute treatments that will address neuropathic pain and other localized pains. The partnership is expected to accelerate the development of various oral and topical opioid-free treatments for pain. The treatments will compete in health care within the US, particularly in the pain management segment which is valued at $40 billion.
Premier Biomedical’s President and CEO William A. Hartman stated that his firm was pleased about the joint venture. Hartman pointed out that ATS will provide a lot in terms of technology and skills and this will be significant towards the development of opioid-free pain management treatments that will be available in the market as early as 2017. The CEO further noted that the ATS joint venture is the first of many joint ventures that Premier Biomedical seeks so as to achieve the goal of introducing effective treatments. The idea is to introduce these treatments to a large number of people within the shortest time possible.
Advanced Technologies Solutions founder and owner Ron LaBorde also said a few words about the joint venture between the two companies. The founder stated that his firm expects to contribute in rapidly reducing the side effects of regular pain relief medicines. He also stated that the technologically advanced methods and synergy derived from the joint venture will guarantee the delivery of natural products. They will employ transdermal and topical delivery as well as the use of technologically advanced methods in the manufacture of the treatments.
The two companies also believe that the joint venture is an opportunity for them to secure more ground in the medicare segment. It will also be an attractive opportunity to showcase their capacity and also attract future partnerships with other firms.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Planning For Phase III Trial for PLX-PAD Cells
Pluristem Therapeutics Inc. (NASDAQ:PSTI)’s Clinical Advisory Board has met to discuss the modalities under which they will carry Phase III trial in assessing PLX-PAD cells in recovery following surgery for hip Fracture. Once everything is in place the company plans to meet with FDA officials to discuss the Phase III protocol.
PLX-PAD cells have already shown they can induce muscle regeneration in patients that have undergone hip replacement surgery in Phase II trials. With the treatment showing a 500% improvement in muscle force and 300% improvement in muscle volume, compared to Placebo group, Pluristem Therapeutics Inc. (NASDAQ:PSTI) remains confident of positive results in Phase III trials.
Given the Phase II clinical trials, Chairman and CEO, Zami Aberman remains confident of PLX-PAD treatment playing an important role in improving the outcome of femoral neck fracture surgeries in future.
